Headache disorders, including migraine and chronic tension-type headache (CTTH), impose a significant global burden on individuals and healthcare systems. Migraine affects approximately one in seven people worldwide and ranks second as a cause of disability in young adults, while CTTH impacts 1-3% of the population, causing persistent pain that disrupts daily functioning (Markin et al., 2022; Rajain et al., 2023). Conventional pharmacological treatments often have limited efficacy and potential side effects, driving the search for safe and effective non-pharmacological alternatives. Repetitive Transcranial Magnetic Stimulation (rTMS) has emerged as a promising option, with growing research highlighting its ability to modulate brain activity and alleviate headache symptoms. This article synthesizes findings from three key studies to explore rTMS’s mechanisms, clinical outcomes, and future directions in treating these debilitating conditions.

Understanding rTMS: Mechanisms of Action

rTMS works by delivering painless magnetic pulses to targeted brain regions, modifying neural activity and functional connectivity (FC) between critical brain networks. Its mechanisms vary slightly based on the headache type but center on restoring balance to disrupted brain function.

For migraine, a study by Markin et al. (2022) focused on episodic migraine without aura, using fMRI to track brain changes post-rTMS. The researchers administered a 5-day course of bilateral rTMS (10 Hz, 60% motor threshold, 900 pulses) targeting the fronto-temporo-parietal junction. They found that rTMS significantly altered FC in three core neural networks: increased FC within the default mode network (DMN) and between the DMN and pain/visual systems, decreased FC between the salience network and sensorimotor/visual networks, and normalized FC in the visual network. These changes suggest rTMS activates antinociceptive (pain-suppressing) mechanisms, reduces hyperattention to pain stimuli, and restores sensory processing balance (Markin et al., 2022).

In CTTH, Rajain et al. (2023) investigated low-frequency rTMS (1 Hz) applied to the right dorsolateral prefrontal cortex (DLPFC). The therapy modulated pericranial muscle overactivity and central pain processing, leading to reduced pain and improved nociceptive thresholds. This aligns with broader research linking headache disorders to excitation-inhibition imbalances in the brain—rTMS helps restore equilibrium by regulating neurotransmitters like glutamate (excitatory) and GABA (inhibitory) (O’Hare et al., 2023). O’Hare et al. (2023) further note that migraine is characterized by thalamocortical dysrhythmia (abnormal communication between the thalamus and cortex) and neurotransmitter imbalances, which rTMS directly addresses by normalizing neural oscillations.

Clinical Efficacy: Evidence from Key Studies

Clinical trials consistently demonstrate rTMS’s ability to reduce headache frequency, intensity, and disability across both migraine and CTTH.

Migraine Outcomes

Markin et al. (2022) studied 19 patients with episodic migraine without aura, finding that 70% (14 out of 19) responded positively to rTMS. Post-treatment, pain intensity (measured via the Numerical Rating Scale) dropped from 7.74 ± 1.45 to 2.42 ± 1.57, and monthly headache days decreased from 9.37 ± 2.91 to 5.95 ± 3.73. These benefits persisted for one month, with pain intensity further declining to 1.75 ± 1.71 and headache days to 5.66 ± 2.42. Non-responders (5 patients) were linked to comorbid depressive symptoms and altered DMN connectivity, highlighting the need for personalized patient selection (Markin et al., 2022).

CTTH Outcomes

Rajain et al. (2023) conducted a randomized controlled trial with 20 CTTH patients, comparing low-frequency rTMS to sham stimulation. The rTMS group showed dramatic improvements: pain scores (Visual Analog Scale) fell from 6.00 ± 1.53 to 1.10 ± 1.13, and Headache Impact Test-6 (HIT-6) scores (measuring daily life interference) decreased from 63.00 ± 5.68 to 42.90 ± 7.09 (p=0.001). Additionally, rTMS reduced pericranial muscle activity (measured via electromyography) and increased nociceptive flexion reflex thresholds, indicating improved pain tolerance. The sham group showed no significant changes, confirming rTMS’s specific therapeutic effect (Rajain et al., 2023).

Long-Term and Mechanistic Insights

O’Hare et al. (2023) emphasize that rTMS’s benefits extend beyond symptom relief by targeting the root causes of headache disorders. For migraine, rTMS normalizes alpha and gamma band oscillations, which are disrupted in migraineurs, and balances glutamate and GABA levels. This addressing of excitation-inhibition imbalances may prevent headache chronification and reduce reliance on acute medications (O’Hare et al., 2023). Both Markin et al. (2022) and Rajain et al. (2023) noted rTMS’s excellent safety profile, with no reported side effects, making it a viable option for patients intolerant to medications.

Patient Selection and Future Directions

While rTMS shows great promise, certain factors influence its effectiveness. For migraine, comorbid depressive symptoms and abnormal DMN connectivity predict non-response, suggesting the need for pre-treatment screening (Markin et al., 2022). For CTTH, accurate targeting of the DLPFC is critical—manual localization may limit efficacy due to individual anatomical variations (Rajain et al., 2023). Future research should focus on:

1. Larger placebo-controlled trials to confirm efficacy across diverse patient populations.
2. Personalized protocols, including neuronavigated targeting and tailored frequencies/durations.
3. Long-term follow-up to assess sustained benefits and prevent chronification.
4. Combining rTMS with other therapies (e.g., vitamin B supplementation, cognitive-behavioral therapy) to enhance outcomes (O’Hare et al., 2023).

Conclusion

Repetitive Transcranial Magnetic Stimulation (rTMS) is a safe and effective non-pharmacological treatment for migraine and chronic tension-type headache. By modulating brain network connectivity, normalizing neural oscillations, and balancing neurotransmitter levels, rTMS reduces pain intensity, frequency, and disability. Evidence from key studies (Markin et al., 2022; Rajain et al., 2023; O’Hare et al., 2023) supports its use as a valuable alternative for patients unresponsive to or intolerant of conventional medications. As research advances, personalized rTMS protocols have the potential to transform headache management, offering long-term relief and improved quality of life for millions worldwide.

References

1. Markin, K., Trufanov, A., Frunza, D., Litvinenko, I., Tarumov, D., Krasichkov, A., Polyakova, V., Efimtsev, A., & Medvedev, D. (2022). fMRI Findings in Cortical Brain Networks Interactions in Migraine Following Repetitive Transcranial Magnetic Stimulation. Frontiers in Neurology, 13, 915346. https://doi.org/10.3389/fneur.2022.915346
2. Rajain, M., Bhatia, R., Tripathi, M., Kumar, N., & Mathur, R. (2023). Low-Frequency Repetitive Transcranial Magnetic Stimulation for Chronic Tension-Type Headache: A Randomized Controlled Study. Cureus, 15(2), e34922. https://doi.org/10.7759/cureus.34922
3. O’Hare, L., Tarasi, L., Asher, J. M., Hibbard, P. B., & Romei, V. (2023). Excitation-Inhibition Imbalance in Migraine: From Neurotransmitters to Brain Oscillations. International Journal of Molecular Sciences, 24(12), 10093. https://doi.org/10.3390/ijms241210093